Back

ABO blood groups and platelet reactivity in patients with coronary artery disease undergoing percutaneous coronary intervention treated with clopidogrel

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cancer and other risk factors for heart disease Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Jiawen Li

Beijing (China)

7 More presentations in this session

Presentation thumbnail
Ischemic and bleeding risk after ST-segment elevated myocardial infarction in patients with active cancer
Doctor M. Dafaalla (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
External validation of the Systematic COronary Risk Evaluation 2 (SCORE2) model in cancer patients
Mrs M. Gynnild (Trondheim, NO)
Abstract Slides Video
Presentation thumbnail
Comparison of cardiovascular disease risk assessment tools for heart failure prediction among cancer patients
Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Cancer-specific Heart Failure (HF) risk score - a new risk score developed specifically to predict HF among cancer survivors
Professor T. Marwick (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Long-term prognostic impact of fasting plasma glucose and myocardial flow reserve beyond other risk factors and heart disease phenotypes
Doctor D. Neglia (Pisa, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Cancer and other risk factors for heart disease

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy
thumbnail
Congress Presentation
Association between clinical ischemic risk and thrombogenicity phenotype and their prognostic prediction in patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
CYP2C19 genetic variants and coronary atherosclerosis: insights beyond antiplatelet therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources